大分割适形放疗在非小细胞肺癌患者中的临床研究  

A clinical study of hypofractionated conformal radiotherapy in non-small cell lung cancer

作　　者：李宏亮[1] 乔岩[1] 李伟[1] 王珂[1] 周立庆[1] LI Hongliang QIAO Yan LI Wei WANG Ke ZHOU Liqing(Department of Radiation Oncology, Huai＇ an Second People＇ s Hospital, Huai＇ an 223302, Jiangsu, Chin)

机构地区：[1]淮安市第二人民医院放疗科,江苏淮安2233020

出　　处：《癌症进展》2017年第5期524-527,共4页Oncology Progress

基　　金：淮安市科技项目(HAS2015013)

摘　　要：目的探讨大分割适形放疗与常规分割适形放疗在非小细胞肺癌(NSCLC)中的临床效果。方法选取68例NSCLC患者作为研究对象,按照随机数字表法分为两组,每组34例。其中对照组患者给予常规分割适形放疗,研究组患者给予大分割适形放疗,观察对比两组患者的近期临床疗效、不良反应发生率及生存率。结果研究组患者治疗总有效率为94.1%,高于对照组患者的73.5%(P﹤0.05);研究组患者3年、5年的生存率分别为88.2%、58.8%,均高于对照组患者的64.7%、32.4%(P﹤0.05);对两组Ⅰ、Ⅱ期及Ⅲ期患者进行分层分析,在早期(Ⅰ、Ⅱ期)患者中,研究组生存率优于对照组(P﹤0.05),而在局部中晚期(Ⅲ期)患者中差异无统计学意义(P﹥0.05);根据肿瘤体积进行分层分析,在肿瘤体积≤90 cm^3的NSCLC患者中,研究组生存率优于对照组(P﹤0.05),而在肿瘤体积﹥90 cm^3的NSCLC患者中,研究组与对照组比较差异无统计学意义(P﹥0.05);研究组患者不良反应发生率为32.4%,与对照组患者的38.2%比较,差异无统计学意义(P﹥0.05)。结论大分割适形放疗治疗NSCLC的临床疗效较好,可有效提高患者生存率,减少不良反应,是一种值得在临床中推广应用的治疗方式。Objective To explore the clinical efficacy of hypofractionated conformal radiotherapy and conventional conformal radiotherapy in non-small cell lung cancer. Method 68 cases of patients with non-small lung cancer were en-rolled and divided into two groups using a random number table, with 34 cases in each group. The patients in control group were given conventional conformal radiotherapy, while the patients in study group were given hypofractionated conformal radiotherapy. The short term clinical efficacy, incidence of adverse reactions and survival rates were compared between two groups. Result The total effective rate of study group was 94.1%, significantly higher than that of the con-trol group （73.5%） （P〈0.05）. The 3-and 5-year survival rate in study group was 88.2%and 58.8%, both higher than those in control group （64.7%, 32.4%, P〈0.05）. Stage-stratified survival rates were calculated for two groups, the results showed：in early stage （stage Ⅰ and Ⅱ） patients, the survival rate of study group was better than that of control group （P〈0.05）;in intermediate and locally advanced patients （stage Ⅲ）, the differences did not reach statistically significance （P〉0.05）. When stratified by tumor volume, the survival rate of study group was higher than that of control group for patients with tumor volume ≤90 cm3 （P〈0.05）, and there was no significant difference found between study group and control group for non-small cell lung cancer patients with tumor volume〉90 cm3 （P〉0.05）. The incidence of adverse reaction was 32.4%in study group and 38.2%in control group, and the difference was not statistically significant （P〉0.05）. Conclu-sion Hypofractionated conformal radiotherapy has achieved a satisfactory clinical efficacy in non-small cell lung can-cer, can effectively improve survive rate of the patients and reduce the incidence of adverse reactions, and is worthy of clinical application.

关 键 词：非小细胞肺癌 大分割适形放疗 常规分割适形放疗 临床疗效 

分 类 号：R734.2[医药卫生—肿瘤]